# United Therapeutics Corporation

> United Therapeutics is a publicly traded biopharmaceutical company that develops and sells medicines for pulmonary hypertension and high-risk neuroblastoma while developing manufactured organs and organ alternatives. Founded by Martine Rothblatt after her daughter developed pulmonary arterial hypertension, it combines a profitable specialty-drug business with long-term transplantation research.

- **Founded:** 1996
- **Headquarters:** Silver Spring and Research Triangle Park, United States
- **Founders:** Martine Rothblatt (Founder, Chairperson and Chief Executive Officer)
- **Products:** Remodulin, Tyvaso, Tyvaso DPI, Orenitram, Adcirca
- **Notable:** First U.S. approval of Remodulin in 2002., FDA approved Unituxin for pediatric high-risk neuroblastoma in 2015., Became a public benefit corporation in 2021.

## Products & services

- **Remodulin** — Treprostinil injection delivered by continuous subcutaneous or intravenous infusion for pulmonary arterial hypertension; initial U.S. approval was for subcutaneous use.
- **Tyvaso** — Nebulized inhaled treprostinil for PAH; its PH-ILD indication was added in 2021. Its proposed IPF use remains investigational as of October 24, 2026.
- **Tyvaso DPI** — Dry-powder inhaled treprostinil for PAH and PH-ILD, developed with MannKind.
- **Orenitram** — Extended-release oral treprostinil for PAH.
- **Adcirca** — Tadalafil tablets for PAH, commercialized through rights licensed from Eli Lilly.
- **Unituxin** — Dinutuximab antibody therapy used in a combination regimen for pediatric high-risk neuroblastoma after a response to prior first-line therapy.
- **Remunity Pump** — Subcutaneous delivery system for Remodulin developed with DEKA; U.S. commercial sales began in 2021.
- **Lung Bioengineering EVLP services** — Commercial centralized ex vivo lung perfusion services support donor-lung evaluation for transplantation.
- **UKidney** — Investigational kidney from a pig with ten gene edits, being evaluated in the EXPAND clinical trial; not an approved commercial organ.
- **ULung** — Preclinical engineered lung alternative based on a printed scaffold populated with cells; not an approved transplantable lung.
- **Ralinepag** — Investigational oral IP receptor agonist for PAH; FDA accepted its application in August 2026 with a June 24, 2027 target action date.
- **Treprostinil SMI** — Investigational soft-mist inhaler program; FDA cleared the phase 2 SUMMIT trial in PH-COPD in October 2026.

## Achievements

- First U.S. approval of Remodulin in 2002.
- FDA approved Unituxin for pediatric high-risk neuroblastoma in 2015.
- Became a public benefit corporation in 2021.
- FDA approved Tyvaso DPI in 2022.
- Reported US$3.1827 billion in 2025 revenue.
- First EXPAND clinical-trial UKidney transplant announced in November 2025.
- Opened third designated pathogen-free xenograft production facility in October 2026.

## Latest updates

- **2026-10** — October 22: authorized up to US$2 billion in additional share repurchases through October 21, 2027; authorization does not require purchases.
- **2026-10** — October 20: opened a third designated pathogen-free xenograft production facility in Houston.
- **2026-10** — October 19: FDA cleared the phase 2 SUMMIT study of investigational treprostinil SMI in PH-COPD.
- **2026-10** — October 14: announced a Liquidia settlement that preserves PAH access to Yutrepia while restricting new PH-ILD prescribing.
- **2026-09** — FDA accepted the nebulized Tyvaso IPF application; company anticipates review completion in late April 2027. IPF use remains investigational.
- **2026-08** — FDA accepted the ralinepag NDA with a June 24, 2027 target action date; drug remains investigational.
- **2026-08** — Reported Q2 revenue of US$783.3 million, down 2% year over year.

## Links

- Website: https://www.unither.com/
- LinkedIn: https://www.linkedin.com/company/unitedtherapeutics/
- Twitter/X: https://twitter.com/unitherfirst
- Instagram: https://www.instagram.com/unitedtherapeutics/
- Facebook: https://www.facebook.com/UnitedTherapeutics

---

Profile page: https://yespress.io/united-therapeutics-corporation
Published by YesPress — https://yespress.io
Last updated: 2026-10-24